NCT05927571 2026-03-05A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)Genentech, Inc.Phase 1 Recruiting120 enrolled